Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Israel

European Research Council grant · Running

NextTPD Next-Gen Targeted Protein Degradation: Directing Disease Proteins to the Proteasome

Coordinator
Bar Ilan University, Israel
Runs
1 January 2026 to 30 June 2027
Status
Running
EU funding
€150k
Total cost
—
Partners
1 organisations in 1 countries
Type
European Research Council grant
Grant agreement
101248639

What the project is doing

In the project's own words, from its summary on CORDIS.

The ubiquitin-proteasome system (UPS) is crucial for maintaining diverse cellular functions through the selective degradation of proteins. Targeted Protein Degradation (TPD) has emerged as an innovative therapeutic strategy that harnesses the UPS to selectively degrade disease-causing proteins. A major advancement in TPD is the use of proteolysis-targeting chimeras (PROTACs), small molecules that bind both an E3 ligase (E3) and the target protein, to induce ubiquitination and subsequent degradation of the target.

While PROTACs have shown promise, their reliance on E3s poses challenges, including tissue-specific expression of E3s, the requirement for accessible ubiquitination sites on target proteins, and potential resistance mechanisms due to E3 mutations. Furthermore, only a small subset of E3s has been successfully utilized for TPD.To address these challenges, this ERC PoC project explores an alternative approach: direct targeting of proteins to the proteasome for degradation, bypassing the need for ubiquitination.

This strategy eliminates reliance on specific E3s and provides a broader, universal approach for proteolysis. During our ERC StG project, using cutting-edge proteomics technology, we identified short peptide motifs that when fused to target proteins, can promote their ubiquitin-independent proteasomal degradation (UbInPD). These findings present a novel opportunity to design PROTACs that directly recruit targets to the proteasome, bypassing the traditional limitations of E3-based systems.

Here, we aim to develop PROTACs incorporating UbInPD short peptide motifs to enhance TPD of model disease-associated proteins, such as the androgen receptor and BRD proteins, for cancer treatment. This approach could significantly broaden the scope of targetable proteins, opening up new avenues for drug discovery. Successful outcomes could lead to groundbreaking therapeutic applications and establish novel, ubiquitin-independent TPD strategies in precision medicine.

Topics

Who is involved

OrganisationCityCountryRole
Bar Ilan UniversityRamat GanIsraelCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI